Detects pathogen-associated molecular patterns (PAMPs) like formylated peptides, aiding bacterial clearance .
Modulates corticotrophin (ACTH) secretion in the pituitary gland, linking innate immunity to neuroendocrine functions .
Interacts with heme-binding protein 1 (Hebp1) to manage oxidative stress responses .
Expressed in mouse vomeronasal organ (VNO) neurons at levels comparable to V1R/V2R chemoreceptors (3.7 neurons per 14 μm section) .
Does not co-express with V1R/V2R receptors, suggesting independent chemosensory pathways .
ELISA Kits: Quantify Fpr-rs6 in tissue homogenates (0.156–10 ng/ml detection range) .
Interaction Studies: STRING database links Fpr-rs6 to Hebp1 (confidence score: 0.738) .
Inflammation Resolution: Fpr-rs6 activation inhibits NF-κB signaling, reducing IL-1β, IL-6, and TNF-α in chorioamnionitis models .
Glucocorticoid Modulation: Co-expressed with Fpr-rs1/rs2 in the anterior pituitary, mediating annexin A1-dependent anti-inflammatory effects .
Pathogen Sensing: Detects formylated peptides from Listeria monocytogenes and mitochondria-derived motifs .
Storage: Short-term at +4°C; long-term at -20°C to -80°C in PBS buffer .
Customization: Available for expression systems, tag placement, and sequence optimization .
Limitations: Requires 5–9 weeks for custom production; not validated for human diagnostics .
What are the optimal conditions for expressing and purifying functional Fpr-rs6 from different host systems?
Optimal conditions for expressing and purifying functional Fpr-rs6 vary significantly across expression systems:
| Expression System | Optimal Conditions | Purification Strategy | Special Considerations |
|---|---|---|---|
| Cell-Free Expression | Temperature: 25-30°C Reaction time: 4-6 hours Reducing environment | Affinity chromatography with His- or GST-tag | Requires optimization of redox conditions for proper folding |
| E. coli | Induction: 0.1-0.5 mM IPTG Temperature: 16-20°C Duration: 16-20 hours | Inclusion body solubilization followed by refolding; affinity purification | Often produces inclusion bodies; may require fusion partners |
| Yeast | Induction: 0.5-2% methanol (P. pastoris) Temperature: 25-28°C Duration: 48-72 hours | Affinity chromatography followed by size exclusion | Monitor glycosylation patterns for consistency |
| Baculovirus | MOI: 1-5 Temperature: 27°C Harvest: 48-72 hours post-infection | Membrane extraction with detergents followed by affinity purification | Requires careful selection of detergents to maintain functionality |
| Mammalian Cell | Transient or stable expression Temperature: 37°C 5% CO₂ Harvest: 48-72 hours | Gentle membrane solubilization followed by affinity and ion exchange chromatography | Most physiologically relevant but lowest yields |
Key purification considerations for maintaining Fpr-rs6 functionality include:
Detergent selection for membrane protein extraction (e.g., DDM, LMNG, or CHS-containing mixtures)
Buffer composition (typically pH 7.4 with physiological salt concentration)
Addition of stabilizing agents during purification (glycerol, specific lipids)
Temperature control throughout the purification process (4°C recommended)
Regardless of the expression system used, the target purity should be ≥85% as assessed by SDS-PAGE for most research applications .
What experimental design considerations are essential when comparing Fpr-rs6 with other formyl peptide receptors?
When designing experiments to compare Fpr-rs6 with other formyl peptide receptors, researchers should address several critical considerations:
Expression Standardization: Ensure comparable expression levels across different receptor subtypes through:
Quantitative flow cytometry for cell surface expression
Western blotting with epitope tags for total expression
Binding site titration with saturating ligand concentrations
Experimental Controls:
Include positive control ligands known to activate specific receptor subtypes
Use receptor-null cells as negative controls
Include cross-desensitization experiments to distinguish receptor-specific effects
Ligand Selection:
Test a diverse panel of formylated and non-formylated peptides
Include receptor-selective agonists and antagonists when available
Use concentration-response curves rather than single concentrations
Data Analysis Approaches:
Apply appropriate statistical methods for comparing potency (EC₅₀/IC₅₀) and efficacy
Use multivariate analysis to identify patterns in receptor response profiles
Consider bias factor calculations for comparing signaling pathway activation
Experimental Design Structure:
Example design matrix for systematic receptor comparison:
| Receptor | Ligand 1 | Ligand 2 | Ligand 3 | ... | Ligand n |
|---|---|---|---|---|---|
| Fpr-rs6 | EC₅₀, Emax | EC₅₀, Emax | EC₅₀, Emax | ... | EC₅₀, Emax |
| Fpr1 | EC₅₀, Emax | EC₅₀, Emax | EC₅₀, Emax | ... | EC₅₀, Emax |
| Fpr2 | EC₅₀, Emax | EC₅₀, Emax | EC₅₀, Emax | ... | EC₅₀, Emax |
| Fpr-rs1 | EC₅₀, Emax | EC₅₀, Emax | EC₅₀, Emax | ... | EC₅₀, Emax |
This systematic approach enables meaningful comparison of pharmacological profiles across receptor subtypes while minimizing experimental biases .